Is COTY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Prestige fragrance as the growth engine, with revenue (ttm) at ~$5.8 billion (fiscal 2026, ended June 30), down ~1% from ~$5.9 billion. The bear case rests on the biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment. Analysts covering it are spread from $1.50 to $4.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $1.50, -53.1% from the $3.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Prestige fragrance as the growth engine. Prestige, dominated by licensed luxury fragrances, is Coty's strongest and most durable business, generating about $772 million of the $1.27 billion in fiscal fourth-quarter sales. The most optimistic analyst target on COTY is $4.00, +25.0% from the $3.20 price. That figure is only reachable if this thesis works close to its best case.

The biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment. The company gave no full-year fiscal 2027 outlook and guided its first quarter to lower like-for-like sales, lower gross margin and lower EBITDA, while an interim (rather than permanent) CEO adds uncertainty about strategic direction. Losing the Gucci license after June 2027 shrinks the prestige portfolio. Even after the Wella sale, the company still carries about $3.1 billion of debt, so profitability pressure from promotions, tariffs and a shift toward lower-margin regions matters. The strategic review of mass brands may not produce attractive sale prices or timing. JAB's controlling majority stake means minority shareholders have limited influence, and beauty demand is cyclical and competitive. Currency swings also move reported results given global exposure, and a share price near $3 can swing sharply: it ranged from about $1.82 to $4.34 over the past year. The most pessimistic published target is $1.50, -53.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Coty Inc is one of the world's largest beauty companies, operating through two reporting segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Prestige fragrance as the growth engine) stalling in the reported numbers rather than in the narrative, the risk above (the biggest risk is execution: Coty is mid-turnaround with declining like-for-like revenue, a fiscal 2026 net loss of about $618 million, and a Consumer Beauty business that took a large non-cash impairment) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon and risk tolerance, and this is not investment advice. Coty is a turnaround story with a strong prestige fragrance business but a fiscal 2026 net loss, about $3.1 billion of debt, an interim CEO and no full-year fiscal 2027 outlook. At about $3.27 a share in mid-October 2026 it trades near 0.5 times sales and above the average analyst target of about $2.66. It may appeal to investors comfortable with volatility and a multi-year recovery, and less so to those wanting stability or income. Research the latest results and decide if the risk fits your plan.

Coty is a global beauty company. It sells prestige products, mainly licensed luxury fragrances from brands like Burberry, Hugo Boss, Calvin Klein and Marc Jacobs (and Gucci until that license returns to Kering), plus Kylie Cosmetics. It also owns mass-market Consumer Beauty brands such as CoverGirl, Rimmel, Max Factor and Sally Hansen. Prestige, dominated by fragrance, makes up roughly 60% of sales, and total fiscal 2026 revenue was about $5.8 billion.

Coty reports two segments. Prestige is the larger one, centered on licensed luxury fragrances and higher-end makeup and skincare, and it has been the stronger performer, with about $772 million of revenue in the June 2026 quarter. Consumer Beauty covers mass cosmetics and skincare brands like CoverGirl and Rimmel, which brought in about $497 million that quarter with like-for-like sales down 3%, and is part of an ongoing strategic review that could lead to divestitures.